Incretin-based therapies are associated with acute pancreatitis: Meta-analysis of large randomized controlled trials

Diabetes Research and Clinical Practice

Volumn 110, Issue 3, 2015, Pages e13-e17

  Roshanov, Pavel S ^a   Dennis, Brittany B ^b  

^a WESTERN UNIVERSITY   (Canada)

^b Peter Boris Centre for Addictions Research McMaster University St Joseph's Healthcare Hamilton   (Canada)

Author keywords

Acute pancreatitis; DDP4 inhibitors; Gliptins; Incretins; Safety

Indexed keywords

ALOGLIPTIN; INCRETIN; SAXAGLIPTIN; SITAGLIPTIN; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR;

ACUTE PANCREATITIS; ARTICLE; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK FACTOR; SENSITIVITY ANALYSIS; STATISTICAL ANALYSIS; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 2; META ANALYSIS; PANCREATITIS; RISK;

DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; PANCREATITIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK;

EID: 84955182639     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2015.10.014     Document Type: Article

References (9)

1. Egan A.G., Blind E., Dunder K., de Graeff P.A., Hummer B.T., Bourcier T., et al. Pancreatic safety of incretin-based drugs - FDA and EMA assessment. N Engl J Med 2014, 370(9):794-797. 10.1056/NEJMp1314078.
2. Li L., Shen J., Bala M.M., Busse J.W., Ebrahim S., Vandvik P.O., et al. Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies. BMJ 2014, 348(April (2)):g2366. 10.1136/bmj.g2366.
3. Wang T., Wang F., Gou Z., Tang H., Li C., Shi L., et al. Using real-world data to evaluate the association of incretin-based therapies with risk of acute pancreatitis: a meta-analysis of 1,324,515 patients from observational studies. Diabetes Obes Metab 2015, 17(1):32-41. 10.1111/dom.12386.
4. White W.B., Cannon C.P., Heller S.R., Nissen S.E., Bergenstal R.M., Bakris G.L., et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013, 369(14):1327-1335.
5. Scirica B.M., Bhatt D.L., Braunwald E., Steg P.G., Davidson J., Hirshberg B., et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013, 369(14):1317-1326.
6. Green J.B., Bethel M.A., Armstrong P.W., Buse J.B., Engel S.S., Garg J., et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015, 373(3):232-242. 10.1056/NEJMoa1501352.
7. Frederich R., Alexander J.H., Fiedorek F.T., Donovan M., Berglind N., Harris S., et al. A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. Postgrad Med 2010, 122(3):16-27. 10.3810/pgm.2010.05.2138.
8. Moores K., Gilchrist B., Carnahan R., Abrams T. A systematic review of validated methods for identifying pancreatitis using administrative data. Pharmacoepidemiol Drug Saf 2012, 21(Suppl. 1 (12)):194-202. 10.1002/pds.2334.
9. Höfler M. The effect of misclassification on the estimation of association: a review. Int J Methods Psychiatr Res 2005, 14(2):92-101.